Inhibitor Binding Region Research Articles

Urinary protein C inhibitor binding region in the Bβ-chain of human fibrinogen

Log in Your account has been temporarily locked Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. For immediate assistance, contact Customer Service: 800-638-3030 (within USA), 301-223-2300 (international) [email protected] Invalid username or password. Try again or register an account. default message Login No user account? Register for free. Register for free. Lippincott Journals Subscribers, use your username or email along with your password to log in. Forgot Password? or Register Register for a free account Existing User Log In Existing User Log In Registered users can save articles, searches, and manage email alerts. All registration fields are required. What's your profession? Academic Medicine Acute Care Nursing Addiction Medicine Administration Advanced Practice Nursing Allergy & Immunology Allied Health Alternative & Complementary Medicine Anesthesiology Anesthesiology Nursing Audiology & Ear and Hearing Basic Science Cardiology Cardiothoracic Surgery Cardiovascular Nursing Cardiovascular Surgery Child Neurology Child Psychiatry Chiropractics Clinical Sciences Colorectal Surgery Community Health Critical Care Critical Care Nursing Dentistry Dermatology Emergency Medicine Emergency Nursing Endocrinology Endoncrinology Forensic Medicine Gastroenterology General Surgery Genetics Geriatrics Gynecologic Oncology Hand Surgery Head & Neck Surgery Hematology/Oncology Hospice & Palliative Care Hospital Medicine Infectious Disease Infusion Nursing Internal/General Medicine Internal/General Medicine Residency Library Sciences Maternal Child Nursing Medical Oncology Medical Research Neonatal/Perinatal Neonatal/Perinatal Nursing Nephrology Neurology Neurosurgery Nursing-administrative Nursing-all Specialties Nursing-education Nutrition & Dietetics Obstetrics & Gynecology Obstetrics & Gynecology Nursing Occupational & Environmental Medicine Oncology Nursing Oncology Surgery Ophthalmology/Optometry Oral & Maxillofacial Surgery Orthopedic Nursing Orthopedics/Spine/Sports Medicine Surgery Otolaryngology Pain Medicine Pathology Pediatric Surgery Pediatrics Pharmacology Pharmacy Physical Medicine & Rehabilitation Physical Therapy & Womens Health Physical Therapy Plastic Surgery Podiatary-general Podiatry-general Primary Care/Family Medicine/General Practice Psychiatric Nursing Psychiatry Psychology Public Health Pulmonology Radiation Oncology/Therapy Radiology Rheumatology Skills & Procedures Sleep Medicine Sport & Exercise/Training/Fitness Sports Medicine Surgical Nursing Transitional Care Transplant Surgery Trauma Nursing Trauma Surgery Urology Womens Health Wound Care Other What's your speciality? Addiction Medicine Allergy & Clinical Immunology Anesthesiology Audiology & Speech-Language Pathology Cardiology Cardiothoracic Surgery Critical Care Medicine Dentistry, Oral Surgery & Medicine Dermatology Dermatologic Surgery Emergency Medicine Endocrinology & Metabolism Family or General Practice Gastroenterology & Hepatology Genetic Medicine Geriatrics & Gerontology Hematology Hospitalist Immunology Infectious Diseases Internal Medicine Legal/Forensic Medicine Nephrology Neurology Neurosurgery Nursing Nutrition & Dietetics Obstetrics & Gynecology Oncology Ophthalmology Orthopedics Otorhinolaryngology Pain Management Pathology Pediatrics Plastic/ Reconstructive Sugery Pharmacology & Pharmacy Physiology Psychiatry Psychology Public, Environmental & Occupational Health Radiology, Nuclear Medicine & Medical Imaging Physical Medicine and Rehabilitation Respiratory/Pulmonary Medicine Rheumatology Sport Medicine/Science Surgery (General) Trauma Surgery Toxicology Transplantation Surgery Urology Vascular Surgery Virology I don't have a medical specialty What's your work setting? Hospital Under 250 Beds Hospital Over 250 Beds Eldercare or Hospice Facility Psychiatric or Rehabilitative Facility Private Practice Group Practice Corporation (Pharmaceutical, Biotechnology, Engineering, etc.) Doctoral University or Medical School Masters or 4-Year Academic University Community College Government Other I have read & acknowledge the End User License Agreement. I have read & accept the terms of the Privacy Policy. Subscribe to journalSubscribe Get new issue alertsGet alerts Submit your manuscript Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Ahead-of-Print For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search

Urinary protein C inhibitor binding region in the Bβ-chain of human fibrinogen

Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Submit your manuscript Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Subscribe Register Login Articles & Issues Current IssuePrevious IssuesPublished Ahead-of-Print For Authors Submit a ManuscriptInformation for AuthorsLanguage Editing ServicesAuthor Permissions Journal Info About the JournalEditorial BoardAdvertisingOpen AccessSubscription ServicesReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search

Characterization of AWN-1 glycosylated isoforms helps define the zona pellucida and serine proteinase inhibitor-binding region on boar spermadhesins

Spermadhesin AWN-1 (14 kDa) belongs to a recently described family of boar sperm surface-associated proteins. AWN-1 is a multifunctional protein which possesses heparin-, serine proteinase inhibitor-, and zona pellucida glycoprotein-binding capability. Therefore it has been implicated in sperm capacitation and sperm-oocyte attachment. Here, we report the characterization of 22–25 kDa isoforms of AWN-1 isolated by heparin-affinity chromatography, which fail to bind to zona pellucida glycoproteins or serine proteinase inhibitors. Our results show that the structure of the high and low molecular mass AWN-1 forms differ in that the former is N-glycosylated at Asp 50 and truncated at the C-terminus. The inability of the glycosylated AWN-1 molecules to bind ligands is due solely to the presence of the oligosaccharide moieties, however. This indicates that glycosylation of AWN-1 may modulate its ligand-binding capabilities. On the other hand, the effect of glycosylation on ligand-binding suggests that both the zona pellucida- and the serine proteinase inhibitor binding domain(s) may be located around the glycosylation point.

Atomic structure of the DNA repair [4Fe-4S] enzyme endonuclease III.

The crystal structure of the DNA repair enzyme endonuclease III, which recognizes and cleaves DNA at damaged bases, has been solved to 2.0 angstrom resolution with an R factor of 0.185. This iron-sulfur [4Fe-4S] enzyme is elongated and bilobal with a deep cleft separating two similarly sized domains: a novel, sequence-continuous, six-helix domain (residues 22 to 132) and a Greek-key, four-helix domain formed by the amino-terminal and three carboxyl-terminal helices (residues 1 to 21 and 133 to 211) together with the [4Fe-4S] cluster. The cluster is bound entirely within the carboxyl-terminal loop with a ligation pattern (Cys-X6-Cys-X2-Cys-X5-Cys) distinct from all other known [4Fe-4S] proteins. Sequence conservation and the positive electrostatic potential of conserved regions identify a surface suitable for binding duplex B-DNA across the long axis of the enzyme, matching a 46 angstrom length of protected DNA. The primary role of the [4Fe-4S] cluster appears to involve positioning conserved basic residues for interaction with the DNA phosphate backbone. The crystallographically identified inhibitor binding region, which recognizes the damaged base thymine glycol, is a seven-residue beta-hairpin (residues 113 to 119). Location and side chain orientation at the base of the inhibitor binding site implicate Glu112 in the N-glycosylase mechanism and Lys120 in the beta-elimination mechanism. Overall, the structure reveals an unusual fold and a new biological function for [4Fe-4S] clusters and provides a structural basis for studying recognition of damaged DNA and the N-glycosylase and apurinic/apyrimidinic-lyase mechanisms.

ChemInform Abstract: Inhibition of Human Sputum Elastase by Substituted 2‐Pyrones.

Nineteen 4-hydroxy- and 4-methoxy-2-pyrones related to elasnin (I) have been assayed for in vitro inhibition of human sputum elastase (HSE), porcine pancreatic elastase, alpha-chymotrypsin, and trypsin. Inhibition is reported as Ki and Ki'; percentage inhibition was dependent on [S] in a number of cases, making it unsuitable as a measure of relative inhibition. The 3-(1-oxoalkyl)-4-hydroxy-6-alkyl-2-pyrones were found to be most effective, the octyl homologue 11 being the most potent inhibitor (Ki = 4.6 microM, 30 times better than the lead compound). A further reduction in inhibition was observed when the hitherto hydrophobic 6-substituent was substituted by a branched functionality of hydrophilic nature. Conversely, methylation of the 4-hydroxy group of the 6-alkyl-2-pyrones increased inhibitory activity. The mechanism of inhibition varied from pure noncompetitive to mixed type to uncompetitive and was found to be dependent on the pattern of substitution. We believe that the 4-hydroxy-2-pyrone binds to the S4 subsite, with the 6-substituent extending across the S4-S1 subsites and the 3-substituent occupying the S5 subsite. The length of the inhibitor binding region was calculated to be approximately 24 A. None of the hydrophobic compounds were found to have any appreciable inhibition (less than 10%) with porcine pancreatic elastase, bovine alpha-chymotrypsin, and bovine trypsin when tested at the limit of their solubility. The hydrophilic compounds were nonspecific, inhibiting all four enzymes. Dialysis was used to show that the interaction is fully reversible.

Inhibition of human sputum elastase by substituted 2-pyrones.

Nineteen 4-hydroxy- and 4-methoxy-2-pyrones related to elasnin (I) have been assayed for in vitro inhibition of human sputum elastase (HSE), porcine pancreatic elastase, alpha-chymotrypsin, and trypsin. Inhibition is reported as Ki and Ki'; percentage inhibition was dependent on [S] in a number of cases, making it unsuitable as a measure of relative inhibition. The 3-(1-oxoalkyl)-4-hydroxy-6-alkyl-2-pyrones were found to be most effective, the octyl homologue 11 being the most potent inhibitor (Ki = 4.6 microM, 30 times better than the lead compound). A further reduction in inhibition was observed when the hitherto hydrophobic 6-substituent was substituted by a branched functionality of hydrophilic nature. Conversely, methylation of the 4-hydroxy group of the 6-alkyl-2-pyrones increased inhibitory activity. The mechanism of inhibition varied from pure noncompetitive to mixed type to uncompetitive and was found to be dependent on the pattern of substitution. We believe that the 4-hydroxy-2-pyrone binds to the S4 subsite, with the 6-substituent extending across the S4-S1 subsites and the 3-substituent occupying the S5 subsite. The length of the inhibitor binding region was calculated to be approximately 24 A. None of the hydrophobic compounds were found to have any appreciable inhibition (less than 10%) with porcine pancreatic elastase, bovine alpha-chymotrypsin, and bovine trypsin when tested at the limit of their solubility. The hydrophilic compounds were nonspecific, inhibiting all four enzymes. Dialysis was used to show that the interaction is fully reversible.